Freitag, 5. März 2021
Navigation öffnen
Anzeige:
Xospata
 
JOURNAL ONKOLOGIE – STUDIE

NIRBTEST New Strategies to Detect Cancers in Carriers of Mutations in RB1

Rekrutierend

NCT-Nummer:
NCT04164134

Studienbeginn:
Dezember 2018

Letztes Update:
18.11.2019

Wirkstoff:
-

Indikation (Clinical Trials):
Retinoblastoma, Neoplasms

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
VU University Medical Center, VU University Medical Center

Collaborator:
University Hospital, Essen, Institut Curie, Ligue contre le cancer, France, , University Hospital, Essen, Institut Curie, Ligue contre le cancer, France

Studienleiter

Armida Fabius
Principal Investigator
VUMC

Kontakt

Studienlocations (3 von 3)

Studien-Informationen

Brief Summary:

Rationale: Individuals with a cancer predisposition due to a mutation in the paradigm tumor suppressor gene RB1, have a high risk to develop the childhood cancer retinoblastoma (Rb). Biopsies are not possible in Rb, before treatment selection. Heritable Rb patients have also a high risk to develop other types of second primary, either childhood or adult, malignancies (SPMs), notably sarcomas and melanomas. Remarkably, SPMs are now the leading cause of death in heritable-Rb-survivors. Unfortunately, there are no well-developed regular surveillance protocols for SPMs in Rb survivors available right now. Recently, new non-invasive cancer test have been developed, based on either RNA-sequencing data from platelets (ThromboSeq), or on extracellular membrane vesicles (EVs) derived from tumor cells present in blood.

Objective:

- Determine the non-cancerous baseline in adult RB1-mutation carriers (heritable-Rb-survivors).

- Contribute to the biobanking of blood and cancerous tissues from RB1-mutation carriers with SPMs.

- The development of blood-based tests, either platelet or EV-based, for the detection of (the type of) tumors in RB1-mutation carriers.

Study design: Cross-sectional multicenter trial.

Study population:

- 40 Rb patients (children),

- 40 controls (children),

- 153 Rb survivors (adults),

- 153 controls (adults),

- 10 Rb survivors with SPM (children/adults).

Main study parameters/endpoints:

- Determine the non-cancerous baseline in adult RB1-mutation carriers (heritable-Rb-survivors).

- Contribute to the biobanking of blood and cancerous tissues from RB1-mutation carriers with SPMs.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Two blood samples totalling 10ml blood will be collected for every participant. Additionally, a short questionnaire has to be filled in concerning their and their family's cancer history. Blood draws will be done, when participants are already present in the hospital for other appointments, and thus no extra visits are required. For all children, blood will be collected through an already present IV, and so no extra venepuncture is required. Children have to be included because Rb is a tumor only present in this patient group.
 

Ein-/Ausschlusskriterien

Inclusion Criteria:

Adult (16 years and older):

- Group 1: germline mutation RB1.

- Group 2 (control): no germline mutation RB1.

Pediatric (until 6 years of age):

- Group 1: somatic or germline mutation RB1 and retinoblastoma.

- Group 2 (control): no mutation RB1.

Exclusion Criteria:

Adult (16 years and older):

- Group 1: concomitant heritable (inherited) disorder other than caused by monoallelic mutation of RB1.

- Group 2 (control): cancer or already known cancer predisposition syndrome.

Pediatric (until 6 years of age):

- Group 1: concomitant heritable (inherited) disorder other than caused by monoallelic mutation of RB1.

- Group 2: cancer or already known cancer predisposition syndrome.

Studien-Rationale

Primary outcome:

1. RNA expression on platelets and allelic DNA balance of EVs in the blood of adult RB1 mutation carriers (Rb-survivors) and retinoblastoma patients (children). (Time Frame - blood will be taken at study inclusion, patients will be followed throughout the study, max 3 years and 9 months.):
blood analyses at time of inclusion to determine baseline



Secondary outcome:

1. RNA expression on platelets, allelic DNA balance of EVs in blood and genomic analysis on tumor tissue of RB1-mutation carriers diagnosed with a second primary malignancy. (Time Frame - blood will be taken at study inclusion, patients will be followed throughout the study, max 3 years and 9 months. In case of second primary tumor a second sample will be taken.):
Comparison of blood at time of inclusion and blood at time of SPM diagnosis versus tumor tissue (if available)
 

Studien-Arme

  • Retinoblastoma patients (children)
    Children that are currently diagnosed with a retinoblastoma. Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken together with standard care blood draw, so no extra venepuncture is required.
  • Controls (children)
    Children with an unrelated problem/condition for which surgery is needed Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken during standard care blood draw, so no extra venepuncture is required.
  • Retinoblastoma survivors (adults)
    Adults that carry a RB1 germline mutation and were diagnosed and treated for retinoblastoma in the past. Blood will be collected and a short questionnaire has to be filled.
  • Controls (adults)
    Healthy adult controls Blood will be collected and a short questionnaire has to be filled.
  • Retinoblastoma survivors with Secondary primary malignancies
    Adults that carry a RB1 germline mutation, were treated for retinoblastoma in the past, and are currently diagnosed with a secondary primary malignancy. Blood will be collected and a short questionnaire has to be filled. Tumor tissue will be collected during surgery.

Geprüfte Regime

  • blood draw:
    Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site. Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Ausgewogene Ernährung reduziert Krebsrisiko

Ausgewogene Ernährung reduziert Krebsrisiko
© Daniel Vincek / Fotolia.com

Mit einer ausgewogenen und ballaststoffreichen Ernährung erhält der Körper nicht nur wertvolle Nährstoffe wie Kohlenhydrate, Eiweiße und Fette, sondern auch wichtige Vitamine, Mineralstoffe und Spurenelemente. Umgekehrt gilt: Mit dem stetigen Bevorzugen bestimmter Lebens- und Genussmittel schadet man der eigenen Gesundheit. „Das heißt, schon mit der Ernährung kann das Risiko für Darmkrebs erhöht oder gesenkt werden“, betont Lars...

Krebstherapien können Herz und Gefäße schädigen: Wie schützt man Patienten?

Krebstherapien können Herz und Gefäße schädigen: Wie schützt man Patienten?
©freshidea / Fotolia.de

Die Therapie von Krebserkrankungen hat in den letzten Jahren große Fortschritte gemacht. Verbesserte Operationsmethoden, eine präzisere Strahlenbehandlung und neue Medikamente konnten die Überlebenschancen der Patienten deutlich verbessern. Doch der Fortschritt hat seinen Preis: „Viele Krebstherapien können Herz und Kreislauf schädigen – auch die modernen, zielsicherer an Krebszellen ansetzenden Wirkstoffe können das Herz-Kreislauf-System in...

Vorsorgevollmacht: Auch für Jüngere relevant

Vorsorgevollmacht: Auch für Jüngere relevant
©deagreez - stock.adobe.com

„Im Moment mache ich mir große Sorgen. Aus den Medien habe ich erfahren, dass ein schwerer Verlauf der Covid-19-Erkrankung auch jüngere Menschen ohne Vorerkrankungen treffen kann. Schutzmaßnahmen wie regelmäßiges Händewaschenund Abstandhalten setze ich alle um. Aber wie regele ich meine Angelegenheiten, falls ich doch erkranke und das so schwer, dass ich meinen Willen nicht mehr äußern kann?“ Martin S., Hannover

Vor der Darmspiegelung ist „Abführen an zwei Tagen“ am effektivsten

Vor der Darmspiegelung ist „Abführen an zwei Tagen“ am effektivsten
© Sebastian Kaulitzki / Fotolia.com

Je sauberer der Darm, umso aussagekräftiger ist das Ergebnis einer Darmspiegelung zur Krebsvorsorge. Darauf weisen Experten im Vorfeld des Kongresses Viszeralmedizin 2016 in Hamburg hin. Um den Darm optimal für die „Koloskopie“ vorzubereiten, sollten Patienten auf zwei Tage verteilt eine Poly-Ethylen-Glykol-Lösung (kurz: PEG) als Abführmittel zu sich nehmen, so die Mediziner. Die Darmspiegelung gilt als eines der effektivsten Verfahren der Krebsvorsorge...